Sanofi looks east with €300m Innovent cancer alliance

Amazon Contraception and family planning Health Pharmaceuticals industry Plan B Roe v. Wade US news US Supreme Court Walmart

Pharmacies reportedly set a purchase limit on emergency contraception pills

Ohio Opioids Opioids crisis Pharmaceuticals industry Walmart

Ohio judge hears if pharmacy chains should pay for driving opioid crisis

Consumer / Employer CVS Health Daily MedCity Influencers News Retail Health SYN Top Story Walgreen Walmart

From picking up groceries to primary care: How digital health can help retailers become a one stop shop  

Artificial Intelligence Consumer / Employer Daily Doctors Health at Scale lab testing News Quest Diagnostics SYN Top Story Walmart

Two announcements involving Walmart show its goal to provide convenience to employees/shoppers

Health IT Machine Learning Walmart

Walmart, Health at Scale Launch Personalized Provider Recommendations to Employees, Families

Amazon Care CVS Health Featured HHCN+ innovation Medically Home Right at Home Walgreens Boots Alliance Walmart

Retail Giants Ready to Disrupt the Home-Based Care Ecosystem

Health IT Inovalon Patient Journey Walmart

Walmart Expands Partnership with Inovalon for Complete View of Patient Journey

Cleveland cvs Daily Legal Ohio opioid epidemic Pharmacy SYN Top Story Walgreens Walmart

Jury rules pharmacy chains liable in landmark opioid trial

Amazon cvs Daily Health Services Pharmacy primary care Retail Health SYN Top Story VillageMd Walgreens Walmart

Walgreens bets all its chips on a new healthcare strategy. Will patients buy in?

Capsule Glen Tullman GoodRx Health Tech Jessica DaMassa Oscar Health transcarent Walmart WTF Health

WTF Health: Transcarent, Walmart & The “Re-making” of Healthcare Payers: Glen Tullman on the Power of Big Retail

Amedisys CareAcademy Encompass Health Hospice Jet Health Ochsner Health System Personal Home Care Staffing Walmart

Walmart Snags Ochsner Executive; Amedisys Names New Hospice Leader

care navigation Daily digital health Health Tech News Retail Health SYN Telehealth Top Story transcarent Walmart Walmart Health

Why Transcarent is sending self-insured companies to Walmart’s health services

Digital Health Hires Health IT Health IT Hires Most Popular Veta Health Walgreens Walmart

Veta Health Apoints CEO, Walgreens Leadership Appointments, Walmart’s New VP, Other Executive Appointments

Glen Tullman Health Tech Jessica DaMassa Livongo start ups transcarent Walmart

Walmart Picks Transcarent: Tullman on First ‘Everyday Low Prices’ Offer for Self-Insured Employers

EMR/EHR Health IT Walmart

Walmart to Deploy Epic EHR Platform in 4 New Health Centers

Featured HHCN+ innovation Walmart

‘We Want to Support People Being in Their Home’: Walmart, Amazon Outline Health Care Strategies

benefits navigation Daily Employee Benefits health insurance Health Services Included Health LGBTQ health Startups SYN Top Story Walmart

How a benefits navigation startup for LGBTQ employees won over big companies

Amazon BioPharma biopharma nl CVS Health Daily drug pricing Legal Payers Pharma Policy SYN Top Story Walmart

Can Amazon change how the PBM and pharmacy worlds operate?

Daily insulin Novo Nordisk Pharma Retail Health SYN Top Story Walmart

Walmart rolls out discounted insulin, but patients still grapple with high prices

Care Coordination digital health Health IT Walmart

Walmart to Offer Included Health’s Care Navigation Platform to LGBTQ+ Employees & Families

birth control pills condoms Healthcare moral objection reproductive health care Roe v. Wade Walgreens

#BoycottWalgreens trends after people say they were denied birth control pills, condoms

Clinical Trials cvs decentralised clinical trials diversity News patients R&D Walgreens

Pharmacy chain Walgreens plans to disrupt clinical trial sector

Care Coordination clinical research Clinical Trial Clinical Trials digital health Life Sciences medical records model patient experience Patient Privacy Pharmacy social determinants of health virtual care Walgreens

Walgreens Launches New Clinical Trial Business to Address Access & Diversity

Help At Home Inc. HHCN+ Kendal at Home Parentis Health Personal touch Home Care Pop-In Care Synergy HomeCare VillageMd Walgreens

Transactions: Kendal at Home Expands Footprint; Help at Home’s Expansion to New York

COPD diabetes Health IT Healthcare Mergers & Acquisitions Heart medication Medication Adherence Patient Education Patient Engagement Physicians Population Health Management Type 2 Diabetes Walgreens

VillageMD Acquires Patient Education Platform Healthy Interactions

Advocate Aurora Enterprises Amedisys Brookdale Senior Living CareCentrix Contessa Health Featured HCA Healthcare HHCN+ Home Health Care Home Instead Senior Care honor hospital at home Humana innovation Kaiser Permanente Kindred at Home Landmark Health M&A Mayo Clinic Medically Home Optum Senior Helpers VillageMd Walgreens

These 8 Deals from 2021 Will Shape the Future of Home-Based Care

Amedisys Aveanna Healthcare Axxess CarePods Contessa Health Home Health Care Home-based primary care M&A MaineHealth Care at Home Personal Home Care SCP Health The Pennant Group UpsideHōM VillageMd Walgreens

From Higher Acuity in the Home to Pandemic-Related Surprises: 7 Under-the-Radar Stories That Shaped 2021

Cleveland cvs Daily Legal Ohio opioid epidemic Pharmacy SYN Top Story Walgreens Walmart

Jury rules pharmacy chains liable in landmark opioid trial

Amazon cvs Daily Health Services Pharmacy primary care Retail Health SYN Top Story VillageMd Walgreens Walmart

Walgreens bets all its chips on a new healthcare strategy. Will patients buy in?

CareCentrix Health Tech Health Technology Jessica DaMassa John Driscoll post-acute care Walgreens WTF Health

CareCentrix CEO on Walgreens Taking Majority Stake, How Post-Acute Care Will Fair in Retail Health

digital health Walgreens

Hims & Hers, Walgreens Expand Personal Care Offerings to 7,000+ Stores and Online Nationwide

Digital Health Hires Health IT Health IT Hires Most Popular Veta Health Walgreens Walmart

Veta Health Apoints CEO, Walgreens Leadership Appointments, Walmart’s New VP, Other Executive Appointments

Ambra Health ClassPass Health in 2 Point 00 Health Tech Intelerad Jessica DaMassa Matthew Holt Mindbody Sprinter Health VillageMd Walgreens Walgreens Health

#Healthin2Point00, Episode 235 | Walgreens Health + VillageMD & CareCentrix, plus more deals

CareCentrix Featured M&A VillageMd Walgreens Walgreens Boots Alliance

Walgreens Jump-Starts ‘Walgreens Health’ by Investing $5.5 Billion in VillageMD, CareCentrix

CareCentrix Daily Health Services primary care Retail Health SYN Top Story VillageMd Walgreens

Walgreens doubles down on VillageMD investment, plans broader health strategy

Arlington Daily Evolent Health Health IT Health Tech M&A Pharmacy Software SYN Top Story Walgreens

Report: Walgreens considers acquiring health IT company Evolent

Covid-19 vaccines CVS Health Daily earnings Pharmacy Retail Health SYN Top Story Walgreens

CVS lowers vaccination expectations, but says more people are coming in for first doses

Daily primary care Retail Health SYN Texas Top Story VillageMd Walgreens

Walgreens shares next step in primary care plans: 29 more clinics in Texas

at-home testing Covid-19 testing cvs Daily Diagnostics over-the-counter Policy SYN Top Story Walgreens Walmart

Pharmacies start selling over-the-counter Covid tests, but they’re too pricey to turn the tide

Chicago Daily IPO primary care Retail Health Startups SYN Top Story VillageMd Walgreens

Report: Walgreens-backed primary care startup planning IPO

Sanofi Headquarters in Paris

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market.

The deal – which includes an option on a second €400 million investment – will see the two companies jointly develop tusamitamab ravtansine (SAR408701), a CEACAM5-targeting antibody-drug conjugate (ADC), as well as a pegylated formulation of interleukin-2 codenamed SAR444245 in China.

Sanofi has already taken the ADC into phase 3 testing outside China as a second or third-line therapy for non-small cell lung cancer (NSCLC), pitching at regulatory filings in the US and Europe next year.

The French group is also testing it in phase 2 trials in gastric cancer and other solid tumours as a monotherapy and in combination with other drugs, including Merck & Co’s Keytruda (pembrolizumab) and Eli Lilly’s Cyramza (ramucirumab).

Innovent is responsible for developing the drug in China, picking up exclusive marketing rights there, with Sanofi in line for up to €80 million in milestone payments as well as royalties on sales if it gets approved.

SAR444245, meanwhile, is a long-acting IL-2 that blocks off part of the molecule that engages with alpha receptors, designed to maintain the anticancer efficacy of the molecule while preventing side effects. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

The structure of the agreement on this drug is a little different, with Innovent developing the drug but Sanofi taking the lead on commercialisation, with the Chinese biotech standing to receive up to €60 million in milestones plus royalties.

Both of the drugs are being developed in combination with Innovent’s PD-1 inhibitor Tyvyt (sintilimab), which has been approved for several indications in China, including NSCLC, hepatocellular carcinoma, oesophageal cancer and Hodgkin lymphoma.

Sintilimab is partnered outside China with Eli Lily, but plans to bring the drug to the US market as a lower-cost rival to current PD-1/PD-L1 drugs were knocked back earlier this year when the FDA declined to approve it on data generated exclusively from Chinese studies.

“This strategic collaboration with Innovent will not only accelerate the development, market access and future commercialisation of two of our key oncology medicines in selected combinations with sintilimab, but also bolster our overall presence in oncology in China,” commented Sanofi’s head of R&D John Reed.

Sanofi isn’t the only multinational pharma group teaming up with Chinese companies to address the rapidly growing oncology market, which according to Allied Market Research, will reach a value of around $13 billion in 2026.

Last year, AstraZeneca signed a deal with Junshi Biosciences to claim marketing rights in China to its PD-1 inhibitor toripalimab, while in 2020, Pfizer paid $200 million for a near-10% stake in CStone, getting Chinese rights to its PD-1 drug sugemalimab.

The post Sanofi looks east with €300m Innovent cancer alliance appeared first on .